Comparable to AZD5991 plus venetoclax, BV6 plus venetoclax demonstrated a synergistic effect to reduce the expression of IAPs (especially XIAP) and c-MYC, and enhanced the activation of caspase 3 and PARP in the two resistant MCL cell lines (Fig. 7E). This evidence concerns the gene MYC and mantle cell lymphoma.